Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Debt: 2018-2025

Historic Total Debt for Arcturus Therapeutics Holdings (ARCT) over the last 4 years, with Mar 2025 value amounting to $15.0 million.

  • Arcturus Therapeutics Holdings' Total Debt was N/A to $15.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.0 million, marking a year-over-year change of. This contributed to the annual value of $60.7 million for FY2022, which is 3.89% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Total Debt of $15.0 million as of Q1 2025, which was down 25.00% from $20.0 million recorded in Q3 2023.
  • Arcturus Therapeutics Holdings' 5-year Total Debt high stood at $63.5 million for Q1 2022, and its period low was $15.0 million during Q1 2025.
  • Its 2-year average for Total Debt is $17.5 million, with a median of $17.5 million in 2023.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Total Debt skyrocketed by 318.07% in 2021, and later slumped by 66.52% in 2023.
  • Arcturus Therapeutics Holdings' Total Debt (Quarterly) stood at $63.1 million in 2021, then declined by 3.89% to $60.7 million in 2022, then crashed by 66.52% to $20.0 million in 2023, then reached $15.0 million in 2025.
  • Its Total Debt stands at $15.0 million for Q1 2025, versus $20.0 million for Q3 2023 and $60.7 million for Q4 2022.